| Customization: | Available |
|---|---|
| CAS No.: | 850649-61-5 |
| Formula: | N/a |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Alogliptin, with the CAS number 850649-61-5, is a medication used to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). It belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the levels of incretin hormones in the body that stimulate insuli release after a meal and reduce the liver's glucose production .
Alogliptin was first approved by the FDA in January 2013 and is available under various brand names such as Nesina, Kazano, and Oseni. The drug is typically prescribed to be taken orally once daily in tablet form, with the standard dose being 25 mg. It can also be found in combination formulations with other diabetes medications like metformin and pioglitazone .
The primary mechanism of action involves inhibiting the DPP-4 enzyme, which would otherwise break down incretin hormones. By blocking DPP-4, alogliptin helps to increase the availability of these hormones, leading to better blood sugar control after meals .
Alogliptin is generally well-tolerated, with common side effects including nasopharyngitis, headache, and upper respiratory tract infection. However, there are potential serious side effects such as pancreatitis, allergic reactions, heart failure, and liver damage that require medical attention . It is important to note that alogliptin is not suitable for patients with type 1 diabetes or those with a history of hypersensitivity to the drug
){kind=link}